- China opens $71 bn 'swap facility' to boost markets
- Asian markets track Wall St record as Hong Kong, Shanghai stabilise
- 'Denying my potential': women at Japan's top university call out gender imbalance
- China's central bank says opens up $70.6 bn in liquidity to boost market
- Youth facing unprecedented wave of violence, UN envoy warns
- 'A casino in every kitchen': Brazil's online gambling craze
- Nobel chemistry winner sees engineered proteins solving tough problems
- Discord seen as online home for renegades
- US forecasts severe solar storm starting Thursday
- Ratan Tata: Indian mogul who built a global powerhouse
- One dead as storm Kirk tears through Spain, Portugal, France
- Indian business titan Ratan Tata dead at 86
- Fed minutes highlight divisions over rate cut decision
- Steve McQueen debuts new WWII film at London festival
- Nobel winners hope protein work will spur 'incredible' breakthroughs
- What are proteins again? Nobel-winning chemistry explained
- AI steps into science limelight with Nobel wins
- Overshooting 1.5C risks 'irreversible' climate impact: study
- Demis Hassabis, from chess prodigy to Nobel-winning AI pioneer
- Global stocks diverge as Chinese shares tumble
- Time runs out in Florida to flee Hurricane Milton
- Chad issues warning ahead of more devastating floods
- Creator's death no bar to new 'Dragon Ball' products
- Chinese stocks tumble on lack of fresh stimulus
- Trio wins chemistry Nobel for protein design, prediction
- Braving war: Lebanon's 'badass' airline defies odds
- US weighs Google breakup in landmark trial
- Chinese stocks tumble on stimulus upset, Asia tracks Wall St higher
- 7-Eleven owner confirms new takeover offer from Couche-Tard
- A US climate scientist sees hurricane Helene's devastation firsthand
- Can carbon credits help close coal plants?
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- The US economy is solid: Why are voters gloomy?
- Scientists sound AI alarm after winning physics Nobel
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Trump secretly sent Covid tests to Putin: Bob Woodward book
- Neural networks, machine learning? Nobel-winning AI science explained
- Boeing delivers 27 MAX jets in September despite strike
- Stock markets diverge as Hong Kong sinks, oil prices fall
- US trade gap narrowest in five months as imports slip
- Stay and 'you are going to die': Florida braces for next hurricane
- Geoffrey Hinton, soft-spoken godfather of AI
- Duo wins Physics Nobel for 'foundational' AI breakthroughs
- German 'Maddie' suspect could be free in 2025 after cleared of separate sex crimes
- China slaps provisional tariffs on EU brandy imports
- Duo wins Physics Nobel for key breakthroughs in AI
- German 'Maddie' suspect could be free soon after cleared of separate sex crimes
'Constant danger': Life after leprosy, a long neglected disease
Dan Izzett has lived with leprosy's effects on his body for 70 years, and has lost much to what he calls an "ancient, fascinating, very unkind disease".
The Zimbabwean former civil engineering technician and pastor was diagnosed at the age of 25 in 1972, but first contracted the disease when he was just five.
That long incubation period gave the bacteria that causes leprosy, Mycobacterium leprae, lots of time to spread through his body.
His right leg was amputated in 1980 in Zimbabwe's capital Harare. Now 75, Izzett has no feeling above his elbows, below his knees or in 70 percent of his face.
That lack of feeling poses a "constant danger," Izzett told AFP in a phone call from his home in southwest England.
In October 2020, "I put my hands on a hot plate and hadn't noticed it until I could smell my flesh burning," he said, leading to the amputation of the middle finger of his right hand.
The following year, the little toe on his left foot was amputated. Last month, he lost another toe.
Izzett said he chose to speak out about his experience because millions of survivors who were less well off were unable to, partly because of the stigma and discrimination that still surrounds the disease.
- The 'forgotten' patients -
Leprosy, also known as Hansen's disease, has been haunting humanity for at least 4,000 years, often affecting the poorest communities.
It is a considered a neglected tropical disease by the World Health Organization, and remains under researched and little discussed compared to many other illnesses.
In 2021, more than 140,500 new cases were detected worldwide, nearly three quarters of them in Brazil, India and Indonesia, according to the WHO.
However pandemic-related disruptions have led to nearly 40 percent fewer cases being detected a year, with fears that tens of thousands have gone undiagnosed.
Even before the pandemic, the official numbers likely did not reflect reality.
"We know the number of patients who have been tested, but we do not count the forgotten, undetected patients," said Bertrand Cauchoix, a leprosy specialist at the Raoul Follereau Foundation in France.
This is in part because the disease's incubation period can last up to 20 years. Testing and diagnosis also takes time, during which patients could potentially infect their family members.
Before he received his diagnosis, said Izzett, "my wife got the disease from me".
Back in the 1970s, Izzett was given the antibiotic Dapsone, which was then a lifetime treatment.
In the mid-80s, a combination of drugs including Dapsone known as multidrug therapy (MDT) became available. It can cure leprosy over a 12-month course -- though nerve damage and other remnants of the disease remain.
Mathias Duck, a former chaplain in Paraguay's capital Asuncion, only needed six-months of MDT after being diagnosed with leprosy in 2010.
"I consider myself the luckiest person affected by leprosy because I was diagnosed and treated in time and so I have no impairments whatsoever," the 44-year-old told AFP.
The WHO provides MDT to patients worldwide for free, with Swiss pharmaceutical giant Novartis donating doses since 2000.
However there has been little progress for new treatments.
"There is no money for leprosy, only charitable donations," Cauchoix said.
- Don't use the 'L word' -
Alexandra Aubry, a specialist at the Centre for Immunology and Infectious Diseases in France, evaluates whether every new antibiotic developed for other illnesses could also be used for leprosy.
Her laboratory is one of the few in the world able to carry out tests on the leprosy bacteria, which does not survive in a petri dish.
They are trying to find a way to "simplify" treatment so it can take less than six months, she said.
There are also a couple of vaccines being developed, though they remain in early phases of human testing.
"It is very complex to get funding for this," Aubry said.
"To assess the effectiveness of a vaccine, you have to follow the vaccinated population for 10 to 15 years," with the timeframe extended further by the disease's long incubation period, she said.
In comparison to how swiftly the world responded to Covid, leprosy efforts are "a drop in the bucket," Duck said, calling for far more research and political action.
But he added that there is something everyone can do for World Leprosy Day on Sunday -- stop using the word "leper".
"We call it the 'L word'," Duck said, describing it as discriminatory.
"It's a little step that most people can do," he added, "to give people affected by leprosy "the dignity they deserve".
U.Ndiaye--CPN